PL3070091T3 - Pochodne benzodioksolu jako inhibitory fosfodiesterazy - Google Patents

Pochodne benzodioksolu jako inhibitory fosfodiesterazy

Info

Publication number
PL3070091T3
PL3070091T3 PL16020112T PL16020112T PL3070091T3 PL 3070091 T3 PL3070091 T3 PL 3070091T3 PL 16020112 T PL16020112 T PL 16020112T PL 16020112 T PL16020112 T PL 16020112T PL 3070091 T3 PL3070091 T3 PL 3070091T3
Authority
PL
Poland
Prior art keywords
phosphodiesterase inhibitors
benzodioxole derivatives
benzodioxole
derivatives
phosphodiesterase
Prior art date
Application number
PL16020112T
Other languages
English (en)
Inventor
Simon Feldbaek Nielsen
Original Assignee
Leo Pharma A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma A/S filed Critical Leo Pharma A/S
Publication of PL3070091T3 publication Critical patent/PL3070091T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
PL16020112T 2010-06-24 2011-06-24 Pochodne benzodioksolu jako inhibitory fosfodiesterazy PL3070091T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US35820910P 2010-06-24 2010-06-24
EP16020112.5A EP3070091B1 (en) 2010-06-24 2011-06-24 Benzodioxole derivatives as phosphodiesterase inhibitors
EP11729889.3A EP2585469B1 (en) 2010-06-24 2011-06-24 Benzodioxole or benzodioxepine heterocyclic compounds as phosphodiesterase inhibitors
PCT/DK2011/000069 WO2011160632A1 (en) 2010-06-24 2011-06-24 Benzodioxole or benzodioxepine heterocyclic compounds phosphodiesterase inhibitors

Publications (1)

Publication Number Publication Date
PL3070091T3 true PL3070091T3 (pl) 2019-09-30

Family

ID=44351701

Family Applications (2)

Application Number Title Priority Date Filing Date
PL16020112T PL3070091T3 (pl) 2010-06-24 2011-06-24 Pochodne benzodioksolu jako inhibitory fosfodiesterazy
PL11729889T PL2585469T3 (pl) 2010-06-24 2011-06-24 Benzodioksol lub związki heterocykliczne benzodiazepiny jako inhibitory fosfodiesterazy

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL11729889T PL2585469T3 (pl) 2010-06-24 2011-06-24 Benzodioksol lub związki heterocykliczne benzodiazepiny jako inhibitory fosfodiesterazy

Country Status (29)

Country Link
US (3) US8980905B2 (pl)
EP (2) EP2585469B1 (pl)
JP (2) JP6174997B2 (pl)
KR (1) KR101864578B1 (pl)
CN (1) CN102958937B (pl)
AU (1) AU2011269429B2 (pl)
BR (1) BR112012032813B1 (pl)
CA (1) CA2802895C (pl)
CY (2) CY1117862T1 (pl)
DK (2) DK3070091T3 (pl)
ES (2) ES2733092T3 (pl)
HR (2) HRP20160919T1 (pl)
HU (2) HUE030081T2 (pl)
IL (1) IL223329A (pl)
LT (2) LT3070091T (pl)
MX (1) MX2012014131A (pl)
MY (1) MY157481A (pl)
NZ (1) NZ603895A (pl)
PL (2) PL3070091T3 (pl)
PT (2) PT3070091T (pl)
RS (2) RS58945B1 (pl)
RU (1) RU2583787C2 (pl)
SG (1) SG186140A1 (pl)
SI (2) SI3070091T1 (pl)
TR (1) TR201909709T4 (pl)
TW (1) TWI507410B (pl)
UA (1) UA109140C2 (pl)
WO (1) WO2011160632A1 (pl)
ZA (1) ZA201209031B (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104822392B (zh) * 2012-11-30 2017-09-08 利奥制药有限公司 抑制活化的t‑细胞中il‑22表达的方法
BR112016029510A2 (pt) * 2014-06-23 2017-08-22 Leo Pharma As métodos para a preparação de um composto, e, composto intermediário.
WO2017089347A1 (en) 2015-11-25 2017-06-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas
PT3390407T (pt) * 2015-12-18 2023-11-03 Union Therapeutics As Métodos para a preparação de compostos heterocíclicos de 1,3-benzodioxole
MX394835B (es) * 2017-06-20 2025-03-24 Union Therapeutics As Metodos para la preparacion de compuestos heterociclicos de 1,3-benzodioxol.
ES2935615T3 (es) 2017-12-15 2023-03-08 Union Therapeutics As Azetidina dihidrotienopiridinas sustituidas y su uso como inhibidores de la fosfodiesterasa
CA3100977A1 (en) 2018-05-21 2019-11-28 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
SG11202107372QA (en) * 2019-01-15 2021-08-30 Union Therapeutics As Modified release tablet formulations containing phosphodiesterase inhibitors
CN118236503A (zh) * 2019-07-24 2024-06-25 星座制药公司 用于治疗癌症的ezh2抑制联合疗法
CN112552276B (zh) * 2019-09-25 2023-03-21 中国科学院上海药物研究所 苯并氧杂卓-5-酮类化合物及其制备方法和用途
BR112023019309A2 (pt) 2021-03-22 2023-10-31 Union Therapeutics As Tratamento de hidradenite supurativa com orismilaste
GB202205715D0 (en) 2022-04-19 2022-06-01 Union Therapeutics As Treatment of neutrophilic dermatoses
GB202306662D0 (en) * 2023-05-05 2023-06-21 Union Therapeutics As Dosage regimen
GB202306663D0 (en) 2023-05-05 2023-06-21 Union Therapeutics As Combination therapy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712298A (en) * 1993-07-02 1998-01-27 Byk Gulden Lomberg Chemische Fabrik Gmbh Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors
GB9507297D0 (en) 1995-04-07 1995-05-31 Rh Ne Poulenc Rorer Limited New composition of matter
ES2258775T3 (es) 1995-05-19 2006-09-01 Kyowa Hakko Kogyo Co., Ltd. Compuestos heterociclicos que contienen oxigeno.
BR9709113A (pt) * 1996-05-20 1999-08-03 Darwin Discovery Ltd Benzofurano carboxamidas e seu uso terapêutico
WO1998022455A1 (en) * 1996-11-19 1998-05-28 Kyowa Hakko Kogyo Co., Ltd. Oxygenic heterocyclic compounds
JP2005060375A (ja) * 2003-07-28 2005-03-10 Kyowa Hakko Kogyo Co Ltd 含酸素複素環化合物
DE10360792A1 (de) 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
AU2005315319B2 (en) * 2004-12-17 2011-07-07 Glenmark Pharmaceuticals S.A. Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders
HRP20140585T1 (hr) * 2007-02-28 2014-09-12 Leo Pharma A/S Inovativni inhibitori fosfodiesteraze
CN101631792B (zh) * 2007-02-28 2013-05-01 利奥制药有限公司 新的磷酸二酯酶抑制剂
MX2014006812A (es) * 2011-12-21 2014-10-13 Leo Pharma As [1,2,4] triazolopiridinas y su uso como inhibidores de fosfodiesterasa.

Also Published As

Publication number Publication date
HUE030081T2 (en) 2017-04-28
EP2585469B1 (en) 2016-05-25
JP2016164168A (ja) 2016-09-08
AU2011269429A1 (en) 2012-12-20
CN102958937A (zh) 2013-03-06
US20130123291A1 (en) 2013-05-16
US20150111915A1 (en) 2015-04-23
RU2583787C2 (ru) 2016-05-10
TW201206940A (en) 2012-02-16
CA2802895A1 (en) 2011-12-29
US8980905B2 (en) 2015-03-17
RU2013103079A (ru) 2014-07-27
HUE044301T2 (hu) 2019-10-28
PL2585469T3 (pl) 2017-07-31
US20160022657A1 (en) 2016-01-28
EP3070091A1 (en) 2016-09-21
CA2802895C (en) 2019-05-21
CN102958937B (zh) 2016-03-30
SI3070091T1 (sl) 2019-08-30
HRP20160919T1 (hr) 2016-10-07
JP2013529602A (ja) 2013-07-22
CY1117862T1 (el) 2017-05-17
DK3070091T3 (da) 2019-07-08
BR112012032813B1 (pt) 2022-02-01
AU2011269429B2 (en) 2015-07-09
EP2585469A1 (en) 2013-05-01
IL223329A (en) 2017-01-31
SG186140A1 (en) 2013-01-30
MY157481A (en) 2016-06-15
TWI507410B (zh) 2015-11-11
IL223329A0 (en) 2013-02-03
ES2733092T3 (es) 2019-11-27
TR201909709T4 (tr) 2019-07-22
ZA201209031B (en) 2014-02-26
RS58945B1 (sr) 2019-08-30
LT3070091T (lt) 2019-07-25
SI2585469T1 (sl) 2016-11-30
DK2585469T3 (en) 2016-08-29
CY1122201T1 (el) 2020-11-25
EP3070091B1 (en) 2019-04-17
MX2012014131A (es) 2013-01-29
US9273064B2 (en) 2016-03-01
PT2585469T (pt) 2016-08-29
BR112012032813A2 (pt) 2016-11-08
US9637499B2 (en) 2017-05-02
HK1182699A1 (zh) 2013-12-06
RS55104B1 (sr) 2016-12-30
KR101864578B1 (ko) 2018-06-07
WO2011160632A1 (en) 2011-12-29
JP6174997B2 (ja) 2017-08-02
ES2584055T3 (es) 2016-09-23
UA109140C2 (uk) 2015-07-27
NZ603895A (en) 2014-10-31
HRP20191136T1 (hr) 2019-09-20
PT3070091T (pt) 2019-07-22
LT2585469T (lt) 2016-10-10
KR20130038341A (ko) 2013-04-17

Similar Documents

Publication Publication Date Title
EP2552208A4 (en) IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS
HUE044301T2 (hu) Benzodioxol-származékok, mint foszfodiészteráz inhibitorok
IL221823A (en) Pipridine-4-Il-Aztidine Derivatives as Jack 1 Suppressors
EP2552214A4 (en) PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS
GB201016880D0 (en) Phosphodiesterase inhibitors
EP2552211A4 (en) INDAZOLYL-PYRIMIDINE AS KINASEHEMMER
ZA201301951B (en) Benzimidazole derivatives as p13 kinase inhibitors
ZA201207285B (en) Arylethynyl derivatives
IL237581B (en) Derivatives of 6-oxo-pyrazinopyrrolopyrimidines
WO2011106105A9 (en) Inhibitors for antiviral use
IL232358A0 (en) Inhibitors of phosphodiesterase type 10a
ZA201207636B (en) Heteroaryl imidazoline derivatives as jak inhibitors
ZA201109340B (en) Pyrimidinones as pi3k inhibitors
IL228103A0 (en) Amino-quinolines as kinase inhibitors
GB201009731D0 (en) Kinase inhibitors
IL224751A (en) Pyrimidine derivatives as fak inhibitors
ZA201209029B (en) Novel pyrimidine derivatives
GB201018996D0 (en) Novel ROCK inhibitors
EP2521451A4 (en) INHIBITORS OF THE HEDGEHOG PATH
EP2379538A4 (en) HETEROCYCLIC COMPOUNDS AS A PHOSOPHODIESTERASE HEMMER
GB201018597D0 (en) Inhibitors
GB201003936D0 (en) Novel inhibitors
GB201006605D0 (en) Novel inhibitors
GB201003502D0 (en) Novel inhibitors
GB201003395D0 (en) Novel rock inhibitors